PDCD1 and cancer: performed an update meta‐analysis to investigate the sex‐related response heterogeneity to cancer immunotherapy and found that females with advanced or metastatic lung cancer could have a dramatically larger benefit from PD‐1 blockade plus chemotherapy.21